Detalles de la búsqueda
1.
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Br J Cancer
; 127(6): 1153-1161, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35739299
2.
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Br J Clin Pharmacol
; 87(3): 1291-1302, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32736411
3.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Lancet Oncol
; 21(5): 645-654, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32224306
4.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Br J Clin Pharmacol
; 86(9): 1836-1848, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32207164
5.
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.
J Pharmacol Exp Ther
; 369(2): 291-299, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30872388
6.
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Invest New Drugs
; 36(2): 240-247, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28819760
7.
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Invest New Drugs
; 36(2): 248-258, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28852909
8.
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Br J Clin Pharmacol
; 84(4): 764-775, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29243287
9.
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Br J Cancer
; 117(9): 1258-1268, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28859059
10.
Academic Cancer Center Phase I Program Development.
Oncologist
; 22(4): 369-374, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28314841
11.
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Invest New Drugs
; 35(3): 386-391, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28102465
12.
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Cancer
; 122(16): 2524-33, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27192055
13.
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Int J Clin Pharmacol Ther
; 53(7): 563-72, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26073352
14.
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1236-45, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25117475
15.
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology
; 13(1): 2290787, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170160
16.
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Invest New Drugs
; 31(2): 417-24, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22918720
17.
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Oncotarget
; 14: 622-636, 2023 06 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335291
18.
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
Clin Cancer Res
; 28(12): 2517-2526, 2022 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302585
19.
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Mol Cancer Ther
; 21(4): 625-634, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131875
20.
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Clin Cancer Res
; 28(13): 2762-2770, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35486638